Wang Junqiao, Yang Yuanjuan, Yang Haitao, Fu Xiaojuan
Wenzhou Peace Plastic Surgery Hospital, Wenzhou, China.
Chongqing Medical and Pharmaceutical College, Chongqing, China.
Postepy Dermatol Alergol. 2022 Oct;39(5):908-912. doi: 10.5114/ada.2022.114925. Epub 2022 Mar 27.
It is elusive to compare the efficacy and safety of abrocitinib 100 mg versus 200 mg once daily in patients with atopic dermatitis.
This meta-analysis aims to explore the influence of abrocitinib 100 mg versus 200 mg on the treatment of atopic dermatitis.
Several databases including PubMed, EMbase, Web of science, EBSCO, and Cochrane library were systematically searched through July 2021. We included randomized controlled trials (RCTs) assessing the effect of abrocitinib 100 mg versus 200 mg for patients with atopic dermatitis.
Four RCTs were included in the meta-analysis. Compared with abrocitinib 100 mg for atopic dermatitis, abrocitinib 200 mg had a remarkably positive impact on IGA response (OR = 1.78; 95% CI: 1.39-2.28; < 0.00001), EASI-75 (OR = 2.03; 95% CI: 1.60-2.57; < 0.00001), NRS response (OR = 1.97; 95% CI: 1.27-3.08; = 0.003), and adverse events (OR = 1.43; 95% CI: 1.11-1.84; = 0.005), but it showed no obvious influence on serious adverse events (OR = 0.59; 95% CI: 0.25-1.37; = 0.22).
Abrocitinib 200 mg is better than abrocitinib 100 mg for the treatment of atopic dermatitis.
比较每日一次服用100毫克与200毫克阿布昔替尼治疗特应性皮炎患者的疗效和安全性尚无定论。
本荟萃分析旨在探讨100毫克与200毫克阿布昔替尼对特应性皮炎治疗的影响。
通过系统检索包括PubMed、EMbase、Web of science、EBSCO和Cochrane图书馆在内的多个数据库，检索时间截至2021年7月。我们纳入了评估100毫克与200毫克阿布昔替尼对特应性皮炎患者疗效的随机对照试验（RCT）。
荟萃分析纳入了四项RCT。与100毫克阿布昔替尼治疗特应性皮炎相比，200毫克阿布昔替尼对IGA反应（OR = 1.78；95%CI：1.39 - 2.28；P < 0.00001）、EASI - 75（OR = 2.03；95%CI：1.60 - 2.57；P < 0.00001）、NRS反应（OR = 1.97；95%CI：1.27 - 3.08；P = 0.003）和不良事件（OR = 1.43；95%CI：1.11 - 1.84；P = 0.005）有显著积极影响，但对严重不良事件无明显影响（OR = 0.59；95%CI：0.25 - 1.37；P =
